Table C Predictors of Pediatric OCD Treatment Response in Studies Combining CBT and Medication
Author (s)
Study Design &
Intervention
N; Age
OCD Outcome
Measure; Timing
of Assessments
Predictors
Examined
Statistically
Predictor Findings
95 w/out tics; 17
w/ tics; 7-17
CY-BOCS
(predicted score)
Tics
Tics associated with poorer
response in medication only
treatment
Randomized Controlled Trials:
March et al.,
2007 29
Randomized
trial: CBT,
sertraline,
combined CBT
and sertraline, or
pill placebo for
12 weeks.
- 12 weeks posttreatment
Uncontrolled Trials:
Wever & Rey,
1997 23
Open trial
82; 7-19
combined tx (12
sessions CBT and
medicationclomipramine or
SSRI)
CY-BOCS
- 4 weeks and 6
months posttreatment
Gender
Age
BL OC Severity
Duration of
illness
Comorbidity
Family
environment
Note: CY-BOCS = Children’s Yale-Brown Obsessive Compulsive Scale.
References (includes all references from original article)
None of the predictors variables
were associated with treatment
response
Among subjects in combined
treatment and including drop outs,
comorbid ODD and higher CBCL
aggression scores predicted
response; higher CBCL
delinquent scores predicted
response at follow up
1.
Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R. Prevalence of
obsessive-compulsive disorder in the British nationwide survey of child mental health. Br J Psychiatry. 2001; 179:324-329.
2.
Zohar AH. The epidemiology of obsessive-compulsive disorder in children and
adolescents. Child Adolesc Psychiatr Clin N Am. 1999; 8:445-460.
3.
POTS. Cognitive-behavior therapy, sertraline, and their combination for children and
adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
JAMA. 2004; 292:1969-1976
4.
Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D. How do risk factors work together? Mediators, moderators, and
independent, overlapping, and proxy risk factors. Am J Psychiatry. 2001; 158:848-856.
5.
O'Kearney RT, Anstey KJ, von Sanden C. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in
children and adolescents. Cochrane Database Syst Rev. 2006; CD004856.
6.
Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a
quantitative review. J Consult Clin Psychol. 1997; 65:44-52.
7.
Freeman JB, Choate-Summers ML, Moore PS, et al. Cognitive behavioral treatment for young children with obsessivecompulsive disorder. Biol Psychiatry. 2007; 61:337-343.
8.
Geller DA, Biederman J, Stewart SE, et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessivecompulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc
Psychopharmacol. 2003; 13 Suppl 1:S19-S29.
9.
March JS, Franklin M, Nelson A, Foa E. Cognitive-behavioral psychotherapy for pediatric obsessive-compulsive disorder. J
Clin Child Psychol. 2001; 30:8-18.
10.
Thomsen PH. Obsessive-complusive disorder: pharmacological treatment. Eur Child Adolesc Psychiatry. 2000; 9 Suppl 1:I76I84.
11.
Turner CM. Cognitive-behavioural theory and therapy for obsessive-compulsive disorder in children and adolescents: current
status and future directions. Clin Psychol Rev. 2006; 26:912-938.
12.
Barrett P, Healy-Farrell L, March JS. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a
controlled trial. J Am Acad Child Adolesc Psychiatry. 2004; 43:46-62.
13.
Bolton D, Luckie M, Steinberg D. Long-term course of obsessive-compulsive disorder treated in adolescence. J Am Acad
Child Adolesc Psychiatry. 1995; 34:1441-1450.
14.
Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A doubleblind controlled study. Arch Gen Psychiatry. 1985; 42:977-983.
15.
Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive
disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001; 40:222-229.
16.
Piacentini J, Bergman RL, Jacobs C, McCracken JT, Kretchman J. Open trial of cognitive behavior therapy for childhood
obsessive-compulsive disorder. J Anxiety Disord. 2002; 16:207-219.
17.
Barrett P, Farrell L, Dadds M, Boulter N. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder:
long-term follow-up and predictors of outcome. J Am Acad Child Adolesc Psychiatry. 2005; 44:1005-1014.
18.
Leonard HL, Swedo SE, Rapoport JL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine
in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry. 1989; 46:1088-1092.
19.
March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a
multicenter randomized controlled trial. JAMA. 1998; 280:1752-1756.
20.
Thomsen PH, Ebbesen C, Persson C. Long-term experience with citalopram in the treatment of adolescent OCD. J Am Acad
Child Adolesc Psychiatry. 2001; 40:895-902.
21.
Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder:
a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004; 43:1387-1396.
22.
Leonard HL, Swedo SE, Lenane MC, et al. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and
adolescents. Arch Gen Psychiatry. 1993; 50:429-439.
23.
Wever C, Rey JM. Juvenile obsessive-compulsive disorder. Aust N Z J Psychiatry. 1997; 31:105-113.
24.
Wagner KD, Cook EH, Chung H, Messig M. Remission status after long-term sertraline treatment of pediatric obsessivecompulsive disorder. J Child Adolesc Psychopharmacol. 2003; 13 Suppl 1:S53-S60.
25.
Masi G, Millepiedi S, Mucci M, Bertini N, Milantoni L, Arcangeli F. A naturalistic study of referred children and adolescents
with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2005; 44:673-681.
26.
Benazon NR, Ager J, Rosenberg DR. Cognitive behavior therapy in treatment-naive children and adolescents with obsessivecompulsive disorder: an open trial. Behav Res Ther. 2002; 40:529-539.
27.
Rosenberg DR, Stewart CM, Fitzgerald KD, Tawile V, Carroll E. Paroxetine open-label treatment of pediatric outpatients with
obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1999; 38:1180-1185.
28.
Himle JA, Fischer DJ, Van Etten ML, Janeck AS, Hanna GL. Group behavioral therapy for adolescents with tic-related and
non-tic-related obsessive-compulsive disorder. Depress Anxiety. 2003; 17:73-77.
29.
March JS, Franklin ME, Leonard H, et al. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy
in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2007; 61:344-347.
30.
Graeff FG, Parente A, Del Ben CM, Guimaraes FS. Pharmacology of human experimental anxiety. Braz J Med Biol Res.
2003; 36:421-432.
31.
Andres S, Boget T, Lazaro L, et al. Neuropsychological performance in children and adolescents with obsessive-compulsive
disorder and influence of clinical variables. Biol Psychiatry. 2007; 61:946-951.
32.
Greisberg S, McKay D. Neuropsychology of obsessive-compulsive disorder: a review and treatment implications. Clin Psychol
Rev. 2003; 23:95-117.
33.
Schultz RT, Evans DW, Wolff M. Neuropsychological models of childhood obsessive-compulsive disorder. Child Adolesc
Psychiatr Clin N Am. 1999; 8:513-31.
34.
Andres S, Lazaro L, Salamero M, Boget T, Penades R, Castro-Fornieles J. Changes in cognitive dysfunction in children and
adolescents with obsessive-compulsive disorder after treatment. J Psychiatr Res. 2008; 42:507-514.
35.
Barrett PM, Dadds MR, Rapee RM. Family treatment of childhood anxiety: a controlled trial. J Consult Clin Psychol. 1996;
64:333-342.
36.
Yaryura-Tobias JA, Grunes MS, Walz J, Neziroglu F. Parental obsessive-compulsive disorder as a prognostic factor in a year
long fluvoxamine treatment in childhood and adolescent obsessive-compulsive disorder. Int Clin Psychopharmacol. 2000;
15:163-168.
37.
Silverman WK, Kurtines WM, Ginsburg GS, Weems CF, Rabian B, Serafini LT. Contingency management, self-control, and
education support in the treatment of childhood phobic disorders: a randomized clinical trial. J Consult Clin Psychol. 1999;
67:675-687.
38.
Treadwell KR, Flannery EC, Kendall PC. Ethnicity and gender in relation to adaptive functioning, diagnostic status, and
treatment outcome in children from an anxiety clinic. J Anxiety Disord. 1995; 9:373-384.
39.
Silverman WK, Kurtines WM, Ginsburg GS, Weems CF, Lumpkin PW, Carmichael DH. Treating anxiety disorders in
children with group cognitive-behaviorial therapy: a randomized clinical trial. J Consult Clin Psychol. 1999; 67:995-1003.
40.
Beidel DC, Turner SM, Morris TL. Behavioral treatment of childhood social phobia. J Consult Clin Psychol. 2000; 68:10721080.
41.
Berman S, Weems CF, Silverman WK. Predictors of outcome in exposure-based cognitive and behavioral treatments for
phobic and anxiety disorders in children. Behavior Therapy. 2000; 31:713-731.
42.
Cobham VE, Dadds MR, Spence SH. The role of parental anxiety in the treatment of childhood anxiety. J Consult Clin
Psychol. 1998; 66:893-905.
43.
Mendlowitz SL, Manassis K, Bradley S, Scapillato D, Miezitis S, Shaw BF. Cognitive-behavioral group treatments in
childhood anxiety disorders: the role of parental involvement. J Am Acad Child Adolesc Psychiatry. 1999; 38:1223-1229.
44.
Walkup JT, Labellarte MJ, Riddle MA, et al. Searching for moderators and mediators of pharmacological treatment effects in
children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003; 42:13-21.
45.
Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and
adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001; 40:773-779.
46.
Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23
cases. J Child Adolesc Psychopharmacol. 1997; 7:157-166.